Compare VanEck Rare Earth/Strategic Metals (REMX) vs Revvity Inc (RVTY) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
VanEck Rare Earth/Strategic Metals vs Revvity Inc — how do they compare? VanEck Rare Earth/Strategic Metals trades at $75.1, while Revvity Inc trades at $124.14 (market cap $14.18B). The key difference: Revvity Inc pays a 0.22% dividend while VanEck Rare Earth/Strategic Metals pays none, and Revvity Inc is trading nearer its 52-week high, VanEck Rare Earth/Strategic Metals nearer its low. Which is the better fit depends on your goals.
| REMX | RVTY | |
|---|---|---|
Sector | Sector/Thematic | Technology |
52-Week High | $109.53 | $130.94 |
52-Week Low | $57.35 | $82.26 |
Market Cap | — | $14.18B |
Enterprise Value | — | $16.50B |
Dividend Yield | — | 0.22% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
REMX trades at $76.72, up 1.4% today, but technical indicators show a bearish trend with moving averages signaling caution. The ETF faces high volatility (~50% annualized) and significant portfolio turnover, making it unsuitable for conservative investors. Recent news highlights institutional interest with Bank of America increasing its stake by 72.1% in the latest quarter (Defense World, August 14, 2026).
The outlook for REMX is mixed—geopolitical tensions and U.S. efforts to secure rare earth supply chains offer long-term potential, but high volatility and China-dependent holdings pose risks. Investors should weigh strategic exposure against the ETF's aggressive risk profile and monitor tariff policies impacting the sector.
RVTY trades at $127.08, down 2.41% on the day, with a bullish technical signal from moving averages and strong support at $126. The company reported Q2 2026 EPS of $1.41, beating estimates, and raised its full-year outlook, driven by diagnostics strength and improved cash flow. Recent news includes the acquisition of Human Cell Design and the launch of the SuperFlex prenatal screening system.
Outlook is positive with 52% analyst buy ratings and a $135.25 consensus price target, implying ~6% upside. Risks include a premium valuation (P/E 61.1) and execution of growth initiatives. Strong institutional interest, such as Bank of New York Mellon's $78.77 million investment, supports confidence in the stock's trajectory.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About VanEck Rare Earth/Strategic Metals
REMX invests in global companies involved in producing, refining, and recycling rare earth and strategic metals. It provides targeted exposure to critical minerals used in high-tech and green energy, with top holdings like Albemarle and Pilbara Minerals.
Read more on REMX →About Revvity Inc
Revvity, Inc., formerly the Life Sciences and Diagnostics businesses of PerkinElmer, is a global provider of scientific and diagnostic solutions. The company focuses on the health and wellness of humanity through its expertise in life science research, detection, imaging, and informatics. Revvity supplies a broad portfolio of instruments, reagents, and services to pharmaceutical companies, academic research institutions, and clinical laboratories worldwide, enabling customers to make advancements in human health.
Read more on RVTY →
